Dynavax Technologies Management

Management criteria checks 2/4

Dynavax Technologies' CEO is Ryan Spencer, appointed in Dec 2019, has a tenure of 4.42 years. total yearly compensation is $5.81M, comprised of 13.1% salary and 86.9% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $2.61M. The average tenure of the management team and the board of directors is 3.3 years and 5.9 years respectively.

Key information

Ryan Spencer

Chief executive officer

US$5.8m

Total compensation

CEO salary percentage	13.1%
CEO tenure	4.4yrs
CEO ownership	0.2%
Management average tenure	3.3yrs
Board average tenure	5.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ryan Spencer's remuneration changed compared to Dynavax Technologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$6m	US$760k	-US$6m
Sep 30 2023	n/a	n/a	US$61m
Jun 30 2023	n/a	n/a	US$111m
Mar 31 2023	n/a	n/a	US$236m
Dec 31 2022	US$6m	US$695k	US$293m
Sep 30 2022	n/a	n/a	US$320m
Jun 30 2022	n/a	n/a	US$228m
Mar 31 2022	n/a	n/a	US$104m
Dec 31 2021	US$5m	US$600k	US$72m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$62m
Dec 31 2020	US$2m	US$515k	-US$75m
Sep 30 2020	n/a	n/a	-US$97m
Jun 30 2020	n/a	n/a	-US$138m
Mar 31 2020	n/a	n/a	-US$129m
Dec 31 2019	US$3m	US$391k	-US$156m

Compensation vs Market: Ryan's total compensation ($USD5.81M) is above average for companies of similar size in the UK market ($USD2.33M).

Compensation vs Earnings: Ryan's compensation has increased whilst the company is unprofitable.

CEO

Ryan Spencer (45 yo)

4.4yrs

Tenure

US$5,810,736

Compensation

Mr. Ryan Spencer serves as Director at Cidara Therapeutics, Inc. from April 2024. He serves as Interim Chief Financial Officer of Dynavax Technologies Corporation since March 29, 2024. He serves as the Chi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ryan Spencer	CEO, Interim CFO & Director	4.4yrs	US$5.81m	0.18% $ 2.6m
David Novack	President & COO	11.2yrs	US$2.99m	0.024% $ 363.1k
Robert Janssen	Chief Medical Officer and Senior VP of Clinical Development	10.8yrs	US$1.88m	0.049% $ 730.6k
Kelly MacDonald	Senior VP & CFO (Leave of Absence)	less than a year	US$2.07m	0.0059% $ 87.5k
Justin Burgess	Chief Accounting Officer & Controller	4yrs	no data	no data
Jeff Coon	Senior VP & Chief Human Resources Officer	5.3yrs	no data	no data
Paul Cox	VP of Investor Relations & Corporate Communications	1.3yrs	no data	no data
John Slebir	Senior VP & General Counsel	2.9yrs	no data	no data
Donn Casale	Senior VP & Chief Commercial Officer	no data	no data	no data
Dong Yu	Senior Vice President of Vaccine Research	3.3yrs	no data	no data
Eric Frings	VP, Site Head & MD for Dynavax GmbH	3.3yrs	no data	no data
Todd Lopeman	Senior Vice President of Technical Operations	3.3yrs	no data	no data

3.3yrs

Average Tenure

58.5yo

Average Age

Experienced Management: 0IDA's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ryan Spencer	CEO, Interim CFO & Director	4.4yrs	US$5.81m	0.18% $ 2.6m
Peggy Phillips	Independent Director	17.8yrs	US$298.73k	0.021% $ 315.3k
Daniel Kisner	Independent Director	13.8yrs	US$290.73k	0.0011% $ 17.1k
Francis Cano	Independent Director	14.5yrs	US$278.73k	0.016% $ 236.9k
Robert Coffman	Member of Scientific Advisory Board	1.3yrs	US$1.83m	no data
Drew Pardoll	Member of Scientific Advisory Board	5.9yrs	no data	no data
Julie Eastland	Independent Director	3.8yrs	US$293.73k	0% $ 0
Stanley Plotkin	Member of Scientific Advisory Board	5.9yrs	US$20.00k	no data
Scott Myers	Independent Chairman of the Board	2.6yrs	US$274.17k	0% $ 0
Miriam Merad	Member of Scientific Advisory Board	5.9yrs	no data	no data
Laura Q. Chow	Member of Scientific Advisory Board	5.9yrs	no data	no data
E. Wherry	Member of Scientific Advisory Board	5.9yrs	no data	no data

5.9yrs

Average Tenure

72.5yo

Average Age

Experienced Board: 0IDA's board of directors are considered experienced (5.9 years average tenure).

Dynavax Technologies Management

Management criteria checks 2/4

Key information

Recent management updates

Dynavax Technologies Corporation, Annual General Meeting, May 23, 2024

President & COO recently sold US$191k worth of stock

President & COO recently sold US$651k worth of stock

President & COO recently sold US$651k worth of stock

Dynavax Technologies Corporation, Annual General Meeting, May 26, 2022

High number of new directors

Recent updates

Dynavax Technologies Corporation to Report Q1, 2024 Results on May 08, 2024

Dynavax Technologies Corporation, Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$0.05 loss per share (vs US$2.32 profit in FY 2022)

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024

Dynavax Technologies Corporation to Report Q4, 2023 Results on Feb 22, 2024

Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.11 (vs US$0.50 in 3Q 2022)

Dynavax Technologies Corporation to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.027 (vs US$1.02 in 2Q 2022)

Dynavax Technologies Corporation to Report Q2, 2023 Results on Aug 03, 2023

Investor sentiment improves as stock rises 16%

President & COO recently sold US$191k worth of stock

Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.26 profit in 1Q 2022)

Full year 2022 earnings released: EPS: US$2.32 (vs US$0.62 in FY 2021)

Dynavax Technologies Corporation to Report Q4, 2022 Results on Feb 23, 2023

President & COO recently sold US$651k worth of stock

President & COO recently sold US$651k worth of stock

Third quarter 2022 earnings released: EPS: US$0.50 (vs US$0.24 loss in 3Q 2021)

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2022

Dynavax Technologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Dynavax Technologies Corporation Announces First Participant Dosed in A Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine

Now 22% undervalued

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$1.02 (vs US$0.039 in 2Q 2021)

Dynavax Technologies Corporation Revises Earnings Guidance for the Year 2022

Dynavax Technologies Corporation to Report Q2, 2022 Results on Aug 04, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Dynavax Technologies Corporation Reaffirms Earnings Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.26 (vs US$0.007 in 1Q 2021)

Dynavax Technologies Corporation to Report Q1, 2022 Results on May 05, 2022

Dynavax Technologies Corporation, Annual General Meeting, May 26, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Dynavax Technologies Corporation Provides Revenue Guidance for the Full Year 2022

Dynavax Technologies Corporation to Report Q4, 2021 Results on Feb 28, 2022

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.04 profit in 3Q 2020)

Forecast to breakeven in 2021

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation Announces Launch of Its Covid-19 Vaccine Mvc-Cov1901 Adjuvanted with Dynavax's Cpg 1018 Adjuvant

Second quarter 2021 earnings released: EPS US$0.039 (vs US$0.53 loss in 2Q 2020)

High number of new directors

Dynavax Technologies Corporation(NasdaqCM:DVAX) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: EPS US$0.008 (vs US$0.15 loss in 1Q 2020)

Full year 2020 earnings released: US$0.75 loss per share (vs US$2.16 loss in FY 2019)

Revenue beats expectations

Dynavax Technologies Corporation Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine

Dynavax Technologies Corporation to Report Q4, 2020 Results on Feb 25, 2021

Dong Yu Joins in Dynavax Technologies Corporation as Senior Vice President of Vaccine Research and A Member of the Executive Team

Dynavax Technologies Corporation and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018

Dynavax Technologies Corporation Enters into an Agreement with the Coalition for Epidemic Preparedness Innovations

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Medigen Vaccine Biologics Corporation Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan

Dynavax Technologies Corporation Appoints Kelly Macdonald as Its Senior Vice President and Principal Financial Officer, Effective March 1, 2021

Dynavax Technologies Corporation Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

Serum Institute of India Partneres with Dynavax Technologies Corporation Jointly Announces First Participants Dosed in the Phase 1/2 Clinical Trial for a Covid-19 Vaccine

European CHMP Adopts Positive Opinion for HEPLISAV-B®, Dynavax's Two Dose Adult Hepatitis B Adjuvanted Vaccine

Third quarter 2020 earnings released: EPS US$0.04

Revenue beats expectations

Medigen Vaccine Biologics Corporation COVID-19 Vaccine Combined with Dynavax Technologies Corporation CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October

Dynavax Technologies Corporation Announces Management Changes

Dynavax Technologies Corporation to Report Q2, 2020 Results on Aug 06, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team